{"id":20463,"date":"2023-10-11T11:29:33","date_gmt":"2023-10-11T09:29:33","guid":{"rendered":"https:\/\/ggba.swiss\/adiposs-completes-the-phase-i-clinical-trial-of-its-flagship-product-imagebat\/"},"modified":"2023-10-11T11:32:20","modified_gmt":"2023-10-11T09:32:20","slug":"adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/","title":{"rendered":"Adiposs cl\u00f4ture l&rsquo;essai clinique de phase I de son produit phare ImageBAT"},"content":{"rendered":"\n<p>Une spin-off notable de l&rsquo;Universit\u00e9 de Gen\u00e8ve, cr\u00e9\u00e9e dans un contexte o\u00f9 41&rsquo;700 nouveaux cas de cancer sont identifi\u00e9s chaque ann\u00e9e rien qu&rsquo;en Suisse, <a href=\"https:\/\/adiposs.com\/technology\/\">Adiposs<\/a> est sp\u00e9cialis\u00e9e dans la lutte contre le syndrome clandestin de la cachexie qui touche 25% des patients atteints de cancer, indirectement par la fonte des muscles et des tissus adipeux.<\/p>\n\n\n\n<p>Son produit phare <a href=\"https:\/\/adiposs.com\/technology\/\">ImageBAT<\/a>, con\u00e7u pour \u00eatre un outil de diagnostic essentiel dans la gestion du cancer, permet de visualiser et de quantifier de mani\u00e8re non invasive la graisse brune activ\u00e9e qui, lorsqu&rsquo;elle est en exc\u00e8s, entra\u00eene un hyperm\u00e9tabolisme corr\u00e9l\u00e9 \u00e0 l&rsquo;\u00e9chec du traitement chez les patients canc\u00e9reux. En outre, sa conception a \u00e9t\u00e9 largement motiv\u00e9e par l&rsquo;ambition de d\u00e9tecter la cachexie avant que la perte de poids et de muscle ne se produise, un exploit jusqu&rsquo;\u00e0 pr\u00e9sent insaisissable en science m\u00e9dicale.<\/p>\n\n\n\n<figure class=\"wp-block-embed aligncenter is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio\"><div class=\"wp-block-embed__wrapper\">\n<iframe loading=\"lazy\" title=\"Q&amp;A with Adiposs (Fongit Innovation Fund)\" width=\"500\" height=\"281\" src=\"https:\/\/www.youtube.com\/embed\/4Y7CFWuH3sM?feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n<\/div><\/figure>\n\n\n\n<p>Andrej Babic, CEO et cofondateur, a d\u00e9clar\u00e9 : \u00ab&nbsp;L&rsquo;ach\u00e8vement de la phase I de l&rsquo;\u00e9tude clinique a \u00e9t\u00e9 un succ\u00e8s.&nbsp;\u00bb L&rsquo;ach\u00e8vement de l&rsquo;essai clinique de phase I est une \u00e9tape importante pour Adiposs. Cet essai repose sur une \u00e9valuation m\u00e9ticuleuse d&rsquo;ImageBAT aupr\u00e8s de trente sujets en bonne sant\u00e9, qui a r\u00e9v\u00e9l\u00e9 des r\u00e9sultats prometteurs en termes de tol\u00e9rance et d&rsquo;innocuit\u00e9, sans aucun \u00e9pisode ind\u00e9sirable grave. Le Dr Herv\u00e9 Porchet, Chief Medical Officer, a expliqu\u00e9 qu&rsquo;il s&rsquo;agissait d&rsquo;un r\u00e9sultat remarquable :&nbsp; \u00ab&nbsp;Les niveaux d&rsquo;exposition \u00e0 ImageBAT et la pharmacocin\u00e9tique \u00e9taient comparables chez les sujets sains et dans nos \u00e9tudes pr\u00e9cliniques.&nbsp;\u00bb<\/p>\n\n\n\n<p>Le succ\u00e8s d&rsquo;Adiposs s&rsquo;explique en grande partie par le fait qu&rsquo;elle a franchi avec succ\u00e8s la phase de d\u00e9veloppement pr\u00e9clinique, qu&rsquo;elle a r\u00e9alis\u00e9 de <a href=\"https:\/\/ggba.swiss\/fr\/adiposs-spin-off-de-luniversite-de-geneve-obtient-chf-100000-pour-combattre-la-cachexie-cancereuse\/\">solides \u00e9tudes de preuve de concept en 2020<\/a> et qu&rsquo;elle a obtenu divers prix et soutiens financiers, tels que le pr\u00eat Tech Seed de 100&rsquo;000 CHF de la Fondation pour l&rsquo;innovation technologique (<a href=\"https:\/\/www.fondation-fit.ch\/fr\/\">FIT<\/a>). La trajectoire vers la phase II, pr\u00e9vue pour 2024 et ax\u00e9e sur les patients atteints d&rsquo;un cancer du poumon avanc\u00e9 en Europe, est attendue avec impatience. Reinhard Stary, pr\u00e9sident du conseil d&rsquo;administration, a d\u00e9clar\u00e9 : \u00ab\u00a0Nous sommes tr\u00e8s enthousiastes \u00e0 la perspective d&rsquo;utiliser ImageBAT chez des patients atteints de cancer pour la premi\u00e8re fois et de progresser dans notre mission d&rsquo;am\u00e9liorer la vie des patients atteints de cancer dans le monde entier.\u00a0\u00bb<\/p>\n","protected":false},"excerpt":{"rendered":"<p>La biotech genevoise Adiposs jette une lueur d&rsquo;espoir sur les perspectives du traitement du cancer et des soins aux patients avec la conclusion r\u00e9ussie de l&rsquo;essai clinique de phase I pour son produit innovant, ImageBAT.<\/p>\n","protected":false},"author":6,"featured_media":20459,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[843],"tags":[1210,1148,1140],"class_list":["post-20463","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-sciences-de-la-vie","tag-diagnostic-fr-2","tag-financing-fr-2","tag-oncology-fr-2"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adiposs cl\u00f4ture l&#039;essai clinique de phase I d&#039;ImageBAT | GGBa<\/title>\n<meta name=\"description\" content=\"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l&#039;essai clinique de phase I de son produit phare innovant, ImageBAT.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adiposs cl\u00f4ture l&#039;essai clinique de phase I d&#039;ImageBAT | GGBa\" \/>\n<meta property=\"og:description\" content=\"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l&#039;essai clinique de phase I de son produit phare innovant, ImageBAT.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-11T09:29:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-10-11T09:32:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"Adiposs cl\u00f4ture l&rsquo;essai clinique de phase I de son produit phare ImageBAT\",\"datePublished\":\"2023-10-11T09:29:33+00:00\",\"dateModified\":\"2023-10-11T09:32:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\"},\"wordCount\":452,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg\",\"keywords\":[\"Diagnostic\",\"Financing\",\"Oncology\"],\"articleSection\":[\"Sciences de la vie\"],\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\",\"url\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\",\"name\":\"Adiposs cl\u00f4ture l'essai clinique de phase I d'ImageBAT | GGBa\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg\",\"datePublished\":\"2023-10-11T09:29:33+00:00\",\"dateModified\":\"2023-10-11T09:32:20+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l'essai clinique de phase I de son produit phare innovant, ImageBAT.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"Adiposs ouvre une nouvelle \u00e8re dans le traitement des patients atteints de cancer en faisant d'ImageBAT un outil r\u00e9volutionnaire dans la d\u00e9tection de l'hyperm\u00e9tabolisme. | \u00a9 Adiposs\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adiposs cl\u00f4ture l&#8217;essai clinique de phase I de son produit phare ImageBAT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adiposs cl\u00f4ture l'essai clinique de phase I d'ImageBAT | GGBa","description":"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l'essai clinique de phase I de son produit phare innovant, ImageBAT.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/","og_locale":"fr_FR","og_type":"article","og_title":"Adiposs cl\u00f4ture l'essai clinique de phase I d'ImageBAT | GGBa","og_description":"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l'essai clinique de phase I de son produit phare innovant, ImageBAT.","og_url":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2023-10-11T09:29:33+00:00","article_modified_time":"2023-10-11T09:32:20+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Pierre-Yves Oehrli","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"Adiposs cl\u00f4ture l&rsquo;essai clinique de phase I de son produit phare ImageBAT","datePublished":"2023-10-11T09:29:33+00:00","dateModified":"2023-10-11T09:32:20+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/"},"wordCount":452,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg","keywords":["Diagnostic","Financing","Oncology"],"articleSection":["Sciences de la vie"],"inLanguage":"fr-FR","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/","url":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/","name":"Adiposs cl\u00f4ture l'essai clinique de phase I d'ImageBAT | GGBa","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg","datePublished":"2023-10-11T09:29:33+00:00","dateModified":"2023-10-11T09:32:20+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"La biotech genevoise Adiposs a achev\u00e9 avec succ\u00e8s l'essai clinique de phase I de son produit phare innovant, ImageBAT.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2023\/10\/Adiposs-ImageBAT-1180x811-1.jpg","width":1180,"height":811,"caption":"Adiposs ouvre une nouvelle \u00e8re dans le traitement des patients atteints de cancer en faisant d'ImageBAT un outil r\u00e9volutionnaire dans la d\u00e9tection de l'hyperm\u00e9tabolisme. | \u00a9 Adiposs"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/fr\/adiposs-cloture-lessai-clinique-de-phase-i-de-son-produit-phare-imagebat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/fr\/"},{"@type":"ListItem","position":2,"name":"Adiposs cl\u00f4ture l&#8217;essai clinique de phase I de son produit phare ImageBAT"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/fr\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20463","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/comments?post=20463"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20463\/revisions"}],"predecessor-version":[{"id":20465,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/posts\/20463\/revisions\/20465"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media\/20459"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/media?parent=20463"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/categories?post=20463"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/fr\/wp-json\/wp\/v2\/tags?post=20463"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}